Decree-Law 15/93
Decree-Law 15/93 is a significant piece of legislation in the field of medicine and healthcare in Portugal. It was enacted on January 22, 1993, and it primarily focuses on the regulation of narcotic drugs and psychotropic substances.
Overview[edit | edit source]
Decree-Law 15/93 is a comprehensive legal framework that regulates the use, production, trade, and possession of narcotic drugs and psychotropic substances. It aims to prevent and combat drug abuse and illicit trafficking, while ensuring the availability of these substances for medical and scientific purposes.
Provisions[edit | edit source]
The law categorizes narcotic drugs and psychotropic substances into four schedules, based on their potential for abuse and therapeutic value. Schedule I includes substances with a high potential for abuse and no recognized medical use, while Schedule IV includes substances with a low potential for abuse and recognized medical use.
The law also establishes a licensing system for the production, trade, and possession of these substances. It sets out the procedures for obtaining a license, the conditions for maintaining it, and the penalties for violations.
Impact[edit | edit source]
Decree-Law 15/93 has had a significant impact on the healthcare sector in Portugal. It has helped to regulate the use of narcotic drugs and psychotropic substances in medical practice, and it has contributed to the fight against drug abuse and illicit trafficking.
Criticism[edit | edit source]
Despite its achievements, the law has also faced criticism. Some argue that it is overly restrictive and hampers the availability of these substances for medical and scientific purposes. Others contend that it does not adequately address the issue of drug addiction and the need for harm reduction strategies.
See also[edit | edit source]
Navigation: Wellness - Encyclopedia - Health topics - Disease Index - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
WikiMD is not a substitute for professional medical advice. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Contributors: Prab R. Tumpati, MD